Bevacizumab-awwb (Mvasi)

Note: this is the first FDA-approved biosimilar. The information below is reproduced from the Bevacizumab (Avastin) page, except for the details of FDA indication.

General information

Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.
Route: IV
Extravasation: neutral

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Carcinoma of unknown primary
• Anaplastic glioma
• Breast cancer
• Cervical cancer
• Cholangiocarcinoma
• Colon cancer
• Esophageal cancer
• Follicular lymphoma
• Glioblastoma
• Hepatocellular carcinoma
• Melanoma
• Mesothelioma
• Neuroendocrine tumor
• Non-small cell lung cancer
• Ovarian cancer
• Pancreatic NET
• Renal cell carcinoma
• Small cell lung cancer
• Soft tissue sarcoma
• Testicular cancer
• Endometrial cancer
• Vascular sarcoma

History of changes in FDA indication

• 9/14/2017: FDA approved for the treatment of patients with the following cancers:
  • Metastatic colorectal cancer, in combination with intravenous 5-fluorouracil–based chemotherapy for first- or second-line treatment.
  • Mvasi is not indicated for the adjuvant treatment of surgically resected colorectal cancer.
  • Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrmidine-oxaliplatin-based chemotherapy for the second-line treatment of patients who have progressed on a first-line bevacizumab product-containing regimen.
  • Non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease.
  • Glioblastoma with progressive disease following prior therapy, based on improvement in objective response rate. No data available demonstrating improvement in disease-related symptoms or survival with bevacizumab products.
  • Metastatic renal cell carcinoma, in combination with interferon alfa.
  • Cervical cancer that is persistent, recurrent, or metastatic disease, in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
  • Note: Bevacizumab (Avastin) has a label for ovarian cancer, which was not included in the initial FDA approval for bevacizumab-awwb.

Also known as

• Code name: ABP 215
• Brand name: Mvasi

References

1. MAPLE: Thatcher N, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Paz-Ares Rodriguez L, Breder V, Ostoros G, Hanes V. Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study. Clin Cancer Res. 2019 Apr 1;25(7):2088-2095. Epub 2019 Jan 7. Erratum in: Clin Cancer Res. 2019 May 15;25(10):3193. link to original article PubMed